Development and evaluation of immunoprotective efficacy of a virus-like particle vaccine against encephalomyocarditis virus
10.16303/j.cnki.1005-4545.2025.05.15
- VernacularTitle:脑心肌炎病毒样颗粒疫苗的制备及免疫保护效果评价
- Author:
Yanfang ZHANG
1
;
Qiong ZHU
;
Jie FU
;
Yaohui FANG
;
Jiayin JIN
;
Danna ZHANG
;
Fei DENG
;
Shengbo CAO
Author Information
1. 华中农业大学动物医学院农业微生物学国家重点实验室,湖北武汉 430070;中国科学院武汉病毒研究所病毒学国家重点实验室,湖北武汉 430071
- Publication Type:Journal Article
- Keywords:
encephalomyocarditis virus(EMCV);
virus-like particles(VLPs);
immunogenicity;
hu-moral response;
Bac-to-Bac expression system;
neutralizing antibodies;
subunit vaccine
- From:
Chinese Journal of Veterinary Science
2025;45(5):994-1001
- CountryChina
- Language:Chinese
-
Abstract:
Encephalomyocarditis virus(EMCV)is a zoonotic pathogen that causes encephalitis and myocarditis as its primary clinical manifestations.To explore effective preventive measures,this study utilized a Bac-to-Bac expression system to insert the EMCV P12A and 3C genes into the pFastBacDual shuttle vector,resulting in the generation of the recombinant baculovirus Ac-P12A-3C.This facilitated the large-scale expression and purification of EMCV virus-like particles(VLPs),which were correctly assembled into particles of approximately 30 nm in diameter,as ob-served by electron microscopy.Immunization and challenge experiments in mice demonstrated that these VLPs could effectively protect against EMCV infection,achieving a protection rate of 100％.Histopathological sections indicated that,compared to the PBS control group,the VLP immuniza-tion group exhibited significantly reduced tissue damage,along with a marked decrease in viral load within the tissues.In piglets,immunization with the VLPs elicited a robust humoral response,with neutralizing antibody titers reaching 1∶320 to 1∶640 after a second immunization,and no signifi-cant adverse reactions were observed throughout the immunization process.This study preliminarily explores the immunogenicity and safety of the VLP vaccine,laying the foundation for the development of a subunit vaccine based on EMCV VLPs and offering a new strategy for the prevention and control of encephalomyocarditis.
